With our initial research and development phase now complete, we are marketing products through physician resellers, at consumer venues across the Internet and creating further enhancements to include a seamless web portal for its physician network due to be completed by June 1st
TAMPA, Fla. (PRWEB) April 30, 2008
The development of Calgenex's products resulted from years of research, funding and testing targeted at soft tissue calcification in the human body and its effects on health.
Dr. Ronald Caputo, Director of Cardiology Research at St. Joseph's Hospital in New York and a Calgenex founder stated, "News organizations and institutions such as the New England Journal of Medicine, CNN, BusinessWeek, the American College of Cardiology and others are reporting on the findings from the University of California that states that 'measuring calcium deposits in the arteries of the heart is a good predictor of future heart disease.' Several of the drugs discussed in these and other studies have not necessarily provided the expected benefits to patients according to recent findings. We believe that Calgenex's product Calci-CLEAR(TM) addresses soft tissue calcification. Along with their other products such as Omeganol(TM), which contains the highest Omega-3 content commercially available, Calgenex provides patients with natural products that improve wellness, cardiovascular health and manage cholesterol."
"With our initial research and development phase now complete, we are marketing products through physician resellers, at consumer venues across the Internet and creating further enhancements to include a seamless web portal for its physician network due to be completed by June 1st," explains Jeff Roman, President and CEO.
Learn More about Dr. Ronald Caputo and St. Joseph's Hospital Cardiology Associates at:
About PanGenex Corporation:
PanGenex pursues business opportunities in the nutraceutical and cardiovascular health industries. The Company has developed and markets novel, patented or patent pending, condition specific nutraceuticals, topical over-the-counter (OTC) drugs and personal care products. Healthy Solutions from Science and Nature. (TM)
Cautionary Statement about Forward-Looking Statements
This press release contains "forward-looking statements," which are statements related to future, not past, events. In this context, the forward-looking statements often include statements regarding our goals, plans, projections and guidance regarding our financial position, results of operations, market position, pending and potential future acquisitions and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of strategic partner incentives, (c) the future regulatory environment, (d) our cost of financing, (e) our ability to complete acquisitions and dispositions and the risks associated therewith, and (f) our ability to retain key personnel. These factors, as well as additional factors, could affect our forward-looking statements. We urge you to carefully consider this information. We undertake no duty to update our forward-looking statements, including our earnings outlook. Statements regarding product have not been evaluated by the Food and Drug Administration. The products discussed are not intended to diagnose, treat, cure or prevent any disease.